TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
May 13 2021 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule
of upcoming data presentations at the American Society of Clinical
Oncology (ASCO) annual meeting, to be held virtually June 4 – 8,
2021 and the European Hematology Association (EHA) annual congress,
to be held virtually June 9 – 17, 2021. Details of the data
presentations are included below.
Michael S. Weiss, the Company’s Executive
Chairman and Chief Executive Officer stated, “We are excited to
share updated data for TG-1701, our novel BTK inhibitor, as a
monotherapy, and as a triple therapy with U2, at the upcoming ASCO
and EHA annual congresses. The EHA abstract released yesterday
included an update from the data most recently presented at the ASH
2020 congress, and we are pleased to see with additional patients
and longer follow-up the data continue to show TG-1701 to
be efficacious and generally well tolerated in combination
with U2. We look forward to updating the abstract data and
presenting at both the upcoming ASCO and EHA annual
congresses.”
Data to be presented at
the ASCO meeting:
Presentation Title: TG-1701, A Selective Bruton
Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination
with Ublituximab and Umbralisib (U2) in Chronic Lymphocytic
Leukemia (CLL) and Lymphoma
- Abstract ID: 7525
- Available on Demand: Friday, June 4, 2021 at 9:00 AM ET
- Session Title: Hematologic Malignancies—Lymphoma and Chronic
Lymphocytic Leukemia
- Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical
Research, and Department of Haematology, Sir Charles Gairdner
Hospital, Nedlands Western Australia, Medical School, University of
Western Australia, Crawley, Western Australia
The above abstract will be available on May 19,
2021, via the ASCO meeting website at www.asco.org.
Data to be presented at
the EHA meeting:
Presentation Title: TG-1701, A Selective Bruton
Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination
with Ubituximab and Umbralisib (U2) in Chronic Lymphocytic Leukemia
(CLL) and Lymphoma
- Abstract Code: EP638
- Available on Demand: Friday, June 11, 2021 at 9:00 CEST
- Session Title: Chronic lymphocytic leukemia and related
disorders - Clinical
- Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical
Research, and Department of Haematology, Sir Charles Gairdner
Hospital, Nedlands Western Australia, Medical School, University of
Western Australia, Crawley, Western Australia
The above abstract is now available via the EHA
meeting website at www.ehaweb.org.
At the time of each presentation, the data
presented will be available on the Publications page, located
within the Pipeline section, of the Company’s website at
www.tgtherapeutics.com/publications.cfm ABOUT TG
THERAPEUTICS, INC.TG Therapeutics is a
fully-integrated, commercial stage biopharmaceutical company
focused on the acquisition, development and commercialization of
novel treatments for B-cell malignancies and autoimmune diseases.
In addition to an active research pipeline including five
investigational medicines across these therapeutic areas, TG has
received accelerated approval from the U.S. FDA for
UKONIQ™ (umbralisib), for the treatment of adult patients with
relapsed/refractory marginal zone lymphoma who have received at
least one prior anti-CD20-based regimen and relapsed/refractory
follicular lymphoma who have received at least three prior lines of
systemic therapies. Currently, the Company has two programs in
Phase 3 development for the treatment of patients with relapsing
forms of multiple sclerosis (RMS) and patients with chronic
lymphocytic leukemia (CLL) and several investigational medicines in
Phase 1 clinical development. For more information,
visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and Linkedin.UKONIQ™ is a
trademark of TG Therapeutics, Inc.Cautionary
StatementThis press release contains forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
include but are not limited to statements regarding the
expectations and plans for the clinical trials evaluating TG-1701
as monotherapy and in combination with UKONIQ™ (umbralisib)
and ublituximab (U2), the availability of results from those
trials, and the potential of TG-1701 as a treatment for CLL.
In addition to the risk factors identified from
time to time in our reports filed with the U.S. Securities and
Exchange Commission, factors that could cause our actual results to
differ materially are the following: the risk that interim,
top-line, or other early clinical trial results, including the
clinical studies evaluating TG-1701 in combination with U2, will
not be reproduced in final data sets or in future studies; the risk
that the safety profile observed with TG-1701 as monotherapy and in
combination with U2, may change as additional patients are exposed
for longer durations; the risk that TG-1701 as monotherapy or in
combination with U2 will not prove to be safe and efficacious; the
uncertainties inherent in research and development; and the risk
that the ongoing COVID-19 pandemic and associated government
control measures have an adverse impact on our research and
development plans or commercialization efforts. Further discussion
about these and other risks and uncertainties can be found in our
Annual Report on Form 10-K for the fiscal year ended December
31, 2020 and in our other filings with the U.S.
Securities and Exchange Commission.
Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We
do not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date
hereof. This press release and prior releases are available at
www.tgtherapeutics.com. The information found on our website is not
incorporated by reference into this press release and is included
for reference purposes only.CONTACT:
Investor Relations Email:
ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4
Media Relations: Email:
media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Sep 2023 to Sep 2024